Ozempic: The biggest Danish hit since the Smørrebrød
Jan 30, 2024•47 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Hey! Down Round is running a sale on premium membership. Sign up in the next week using this link, and you can get an annual membership for $49 instead of the usual $70.
This week we're talking about the much-hyped weight loss drug Ozempic and its producer, Danish pharma giant Novo Nordisk. Thanks to the crazy success of Ozempic, Novo Nordisk is now literally the biggest company in Europe by market cap. Now the vultures are circling, and a whole bunch of drugmakers are rushing competitors to market.
We talk about the drug, the company, it's weirdly 'techy' marketing and where it fits into the incoming universe of biotech and pharma tech.
Links
- Our episode from last year with Tim Doyle, founder of Australian online pharmacy Eucalyptus.
- Weight-loss drug maker Novo Nordisk becomes Europe’s most valuable company – FT
- Ozempic is on the rise. That could be a problem for food companies – CNN
See omnystudio.com/listener for privacy information.
For the best experience, listen in Metacast app for iOS or Android